Technology Overview

Innovative Innovations

iNtRON's Platform Technology

iNtRON's platform technology consists of PHAGERIARUS® technology to develop “Immune & Immunotherapeutics” and itLysin® to develop “Anti-Infectious Diseases Drugs”, PHAGERIA®, PHAGERUS®, and im-MucoDr® mRNA-related technologies.

We have expanded our Target Disease Area through long experience and verification. Our platform technologies can be divided into (1) “BC” (Before Concept, Before anti-Cancer Immunotherapeutics) Era before the development of “Immune & Immunotherapeutics” and (2) “AD” ( After New Definition/Doctrine, After Anti-Infectious Disease Drugs) Era.

The core of PHAGERIARUS® is to view bacteriophages as foreign substances that invade the human body, such as bacteria and viruses. In other words, it presents a new perspective on the immune system in the human body in relation between bacteria, viruses, and bacteriophages. We are developing PHAGERIARUS® as a core technology for developing a number of immunotherapeutics, including immuno-cancer drugs, through the paradigm shift of existing immunology.

Our first development goal is immunotherapy for cancer. Immune regulators will be developed using our PHAGERIARUS® technology, resulting in immunotherapeutics. Furthermore, we will develop new drugs to treat various immune diseases, such as Alzheimer's, Parkinson's, and Diabetes using immune system regulators.

Our Technologies

After Definition/Doctrine
fter anti-infectious Disease Drug
AD Era
Before Concept
efore anti-Cancer Immunotherapeutics
BC Era

Development of a number of immunotherapeutics through the development of new BΦPTA or Immune Regulators based on ViP-Cycle


Development of treatments and vaccines targeting viral infectious diseases based on the similarity between bacteriophages and viruses


Development of new biopharmaceuticals targeting CRC, PD, and AD by regulating the gut microbiome with bacteriophages that respond to bacteria


Development of new biopharmaceuticals targeting bacterial infections including antibiotic-resistant bacteria by using engineered endolysin based on itLysin® technology